Title
Neuropathic Pain Unmasks Delta Opioid Receptor-Mediated Analgesia

Permalink
https://escholarship.org/uc/item/8xj2t3z2

Authors
Ong, EW
Holdridge, SV
Sutherland, KA
et al.

Publication Date
2016-04-01

License
CC BY 4.0

Peer reviewed
Neuropathic Pain Unmasks Delta Opioid Receptor-Mediated Analgesia

Edmund W. Ong, Sarah V. Holdridge, Karen Anne Sutherland, Stacey A. Armstrong, Anna M.W. Taylor, Lihua Xue, and Catherine M. Cahill

Abstract

Clinically-used opioid drugs overwhelmingly act at the mu-type opioid receptor (MOPr). MOPr agonists are good analgesics and are the gold-standard for treating moderate and severe pain. However, MOPr agonists are considerably less effective in treating neuropathic pain. Delta-type opioid receptor (DOPr) agonists also have analgesic effects, but none are yet used clinically.

Here, we use in vivo models of neuropathic pain to examine the analgesic effects of DOPr agonists. First, we show that spinally-administered DOPr agonists (DPDPE, SNC80, Deltorphin II, and DSLET) are antiallodynic in neuropathic pain, as has previously been reported. Second, we demonstrate that DOPr-mediated thermal antinociception is, in fact, augmented in neuropathic pain. That is, DOPr agonists produce greater thermal antinociception to the same noxious stimulus in neuropathic animals than in control animals. This is in contrast to the MOPr agonist morphine, which produces less thermal antinociception in neuropathic pain (mirroring the reduction in clinical efficacy). Interestingly, despite all tested DOPr agonists being antiallodynic in neuropathic pain, only two (Deltorphin II and DSLET) show augmented thermal antinociception. These data expand on previous reports demonstrating that DOPr activation modulates thermal nociception. Further, the divergent effects at MOPr and DOPr in neuropathic pain demonstrate that DOPr agonists produce thermal antinociception via DOPr, not MOPr.

Third, we assess the effect of DOPr agonism on integrated neuropathic pain affect using the conditioned place preference (CPP) paradigm. Spinally-administered Deltorphin II produces CPP in neuropathic animals, but not controls.

Fourth, we show that blockade of DOPRs by the antagonist Naltrindole produces a conditioned place aversion (CPA) in neuropathic animals, but not controls. This confirms and extends literature reports that genetic knockout of DOPr is pronociceptive and suggests the presence of DOPr-mediated endogenous analgesia in neuropathic pain.

Fifth, we use neonatally-administered capsaicin to ablate capsaicin-sensitive primary afferents. Destruction of these neurons prevents the augmentation of DOPr-mediated thermal antinociception in neuropathic pain, implicating these peripheral afferents as potential sites of action. Contrastingly, the ablation of capsaicin-sensitive primary afferents does not affect DOPr-mediated antiallodynic effects in neuropathic pain.

The results provide further evidence that neuropathic pain leads to the unmasking of DOPr-mediated analgesia and augmentation of its endogenous activity. Meanwhile, the selective sensitivity to neonatal capsaicin suggests a role for neuronal type-specific, ligand-biased agonism in DOPr analgesia.

Support or Funding Information

This work was supported by grants from the Canadian Institutes of Health Research (MOP121915, MOP394808), the Canada Research Chairs Program, Pfizer Canada, the J.P. Bickell Foundation, the Harry Potterell Foundation, and the Ontario Innovation Trust/Canadian Foundation for Innovation to CMC. EWO was a recipient of a postgraduate scholarship from NSERC. SVH was a recipient of a postgraduate fellowship from Queen’s University.

Footnotes

This abstract is from the Experimental Biology 2016 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

We recommend

Peptidomimetics Exhibiting Mu Opioid Receptor (MOPr) Agonist/Delta Opioid Receptor (DOPr) Antagonist Activity as Novel Pain Therapeutics
Nicholas Griggs et al., FASEB J, 2016

Analgesic effects of opioids can be mediated via immune cells
AZoNetwork, 2017

Viberzi Side Effects, Costs, Dosing, And Prescribing Information For Irritable Bowel Syndrome (IBS) Diarrhea
Neuropathic Pain Unmasks Delta Opioid Receptor-Mediated Analgesia

9/26/2017

Thomas Joaquín Fernández et al., FASEB J, 2017

Efficacy at the Mu Opioid Receptor: Insights from Orthosteric and Allosteric Ligands
Kathryn E Livingston et al., FASEB J, 2016

Allosteric Modulation of the Mu-Opioid Receptor: Probe Dependence and Role of Na+ Ions
Kathryn Livingston and John Traynor, FASEB J, 2015

A biased mu-opioid receptor positive allosteric modulator that does not alter receptor regulation
Kathryn E Livingston and John R Traynor, FASEB J, 2016

Nhan Le et al., RxConsult

Researchers discover tolerance mechanism in chronic morphine treatment
AZoNetwork, 2010

International study shows potential new therapy to treat patients with neuropathic pain
AZoNetwork, 2015

SLU researcher discovers way to block pain pathway
AZoNetwork, 2014